UNC Health — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$86,100	10
2024	Research	$65,855	11
2023	Research	$91,080	12
2022	Research	$88,061	11
2021	Research	$210,043	22
2020	Research	$57,904	4

Breakdown

Who paid Research payments · program years 2020–2025

Merit Medical Systems Inc $272,133 42 payments
Alexion Pharmaceuticals, Inc. $257,355 25 payments
Pfizer Inc. $69,556 3 payments

Studies the money was for Research payments · program years 2020–2025

The Merit Wrapsody AV Access Efficacy Study $272,133 42 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Nave Adult Patients With Generalized Myasthenia Gravis $98,109 8 payments
An Interventional Openlabel Randomized Multicenter Phase 3 Study of Pf07220060 Plus Letrozole Compared to Cdk46 Inhibitor Plus Letrozole in Participants Over 18 Years of Age With Hormone Receptor Hrpositive Her2negative Advancedmetastatic Breast Cancer Who Have Not Received Any Prior Systemic Anticancer Treatment for Advancedmetastatic Disease Fourlight3 $69,556 3 payments
An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis $48,889 7 payments
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) $35,508 2 payments
Preclinical Studies of Complement Activation Modulation in the Treatment of Glomerulonephritis and Vasculitis Caused by Anti-neutrophil Cytoplasmic Autoantibodies (ANCA) $32,662 1 payment
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) $28,004 2 payments
Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies $14,182 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.